The ABSORB III Randomized Controlled Trial (RCT) is a clinical study designed to evaluate the safety and effectiveness of the Absorb™ Bioresorbable Vascular Scaffold (BVS) compared to the XIENCE stent in patients with coronary artery disease. The trial includes patients with up to two new coronary artery lesions and aims to support the pre-market approval of Absorb BVS in the United States. The study also features a lead-in phase to assess physician training and an imaging cohort to evaluate long-term vascular function.